Home-based VR neurofeedback for adolescents with migraine

Feasibility of Home-based Immersive Neurofeedback Self-regulation Training (INSeRT) for Youth With Migraine

Not applicable Interventional Children's Mercy Hospital Kansas City · NCT07454798

This program tests whether a home-based virtual reality system guided by a wearable EEG headband can help adolescents (ages 10–16) who have migraine.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment38 (estimated)
Ages10 Years to 16 Years
SexAll
SponsorChildren's Mercy Hospital Kansas City Academic / other
Locations1 site (Kansas City, Missouri)
Trial IDNCT07454798 on ClinicalTrials.gov

What this trial studies

The trial enrolls adolescents with migraine and begins with a 4-week baseline period of headache logs and questionnaires plus a lab-based EEG assessment of cortical reactivity. Participants are then randomized to either Immersive Neurofeedback Self-Regulation Training (INSeRT), which uses real-time EEG to guide a VR experience, or to a comparison immersive VR imagery condition without neurofeedback or guided relaxation. The intervention is delivered at home via a wearable EEG headband paired with VR sessions, and adherence, retention, and completion of procedures are tracked to determine feasibility and acceptability. The study also collects preliminary headache-related outcome data to look for signals of reduced disability or symptom improvement.

Who should consider this trial

Good fit: Ideal candidates are ages 10–16 with a specialist diagnosis of migraine (with/without aura or chronic), experiencing at least four migraine headaches per month with headache-free intervals, who can tolerate VR/headset use and do not have contraindicating conditions.

Not a fit: Patients with a history of epilepsy or photosensitive seizures, clinically elevated vestibular symptoms, significant physical/psychiatric/developmental limitations, recent start of a new preventive migraine medication, or current behavioral migraine therapy are unlikely to benefit or be eligible.

Why it matters

Potential benefit: If successful, the program could offer adolescents a convenient, nonpharmacologic home-based tool to reduce migraine-related symptoms and disability.

How similar studies have performed: Neurofeedback and VR approaches have shown preliminary promise in small or clinic-based studies, but home-based EEG-guided VR for pediatric migraine is novel and not yet well tested.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 10-16 years (inclusive)
* Diagnosis of migraine (with or without aura, or chronic migraine) by a qualified headache specialist
* At least 4 migraine headaches per month
* Presence of headache-free periods between migraine episodes

Exclusion Criteria:

* Significant physical, psychiatric, or developmental conditions that would limit ability to participate in study procedures
* Clinically elevated Pediatric Vestibular Symptoms Questionnaire (PVSQ) score (\>0.68) or new/worsening vestibular symptoms prior to randomization
* Initiation of a new migraine preventive medication within 4 weeks prior to randomization
* Current participation in behavioral treatment for migraine (e.g., cognitive behavioral therapy or biofeedback)
* History of epilepsy or photosensitive seizures

Where this trial is running

Kansas City, Missouri

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions MigraineHeadache Disorders, PrimaryPediatric migraineAdolescentsNeurofeedbackVirtual realityElectroencephalogramEEG
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.